About Kala Pharmaceuticals, Inc
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company’s product candidates include EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development programs comprise KPI-285/KPI-286, a receptor tyrosine kinase inhibitor program for the treatment of various retinal diseases; SEGRM program, a novel class of compounds designed to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway; and surface targeted steroid program (KPI-333), a new chemical entity as a topical steroid that targets the ocular surface. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472
Kala Pharmaceuticals, Inc News and around…
Latest news about Kala Pharmaceuticals, Inc (KALA) common stock and company :
Gainers CASI Pharmaceuticals (NASDAQ:CASI) shares moved upwards by 19.02% to $1.11 during Friday's after-market session. ...
Kala Pharmaceuticals Inc(NASDAQ: KALA)has acquiredCombangio Inc, a private company developing regenerative ...
Kala Pharma (KALA) delivered earnings and revenue surprises of 4.44% and -40.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference Call and Webcast at 10:30 a.m. ET -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported
-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial ---- Kala expects to initiate Phase 2/3 trial in 3Q 2022 ----Mark S. Blumenkranz, M.D., Professor Emeritus in the Department of Ophthalmology at Stanford University, appointed to Kala’s Board of Directors ---- Management to host co
WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has changed the time of its previously scheduled financial results conference call and live audio webcast. The Company will now report its third quarter 2021 financial results and provide a business update on Monday, November 15
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third ...
Biotech stocks declined for the second straight week amid a broader market pullback, along withearnings news from small- and ...
Kala Pharmaceuticals (NASDAQ:KALA) is set to give its latest quarterly earnings report on Monday, 2021-11-15. Here's what investors ...
WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in November 2021: Jefferies London Healthcare ConferenceA pre-recorded fireside chat will be made available on the company’s website beginning Thu
WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2021 financial results on Monday, November 15, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:30 a.m. ET. The dial-in num
Gainers Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both ...
Gainers Progenity (NASDAQ:PROG) shares increased by 33.17% to $2.85 during Monday's regular session. As of 12:30 ...
Gainers Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints ...
WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the appointment of C. Daniel Myers to its Board of Directors. Mr. Myers, who has more than 35 years of ophthalmic pharmaceutical experience, will serve as a Class III director, and join both the Compensation and Nominating and Corporate
Investors in Kala Pharmaceuticals Inc (KALA) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the KALA options chain for the new December 17th contracts and identified the following call contract of particular interest.
Gainers Statera BioPharma (NASDAQ:STAB) shares rose 16.9% to $3.32 during Friday's regular session. The market value ...
Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) shares moved upwards by 29.96% to $7.72 during Friday's pre-market ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
The big shareholder groups in Kala Pharmaceuticals, Inc. ( NASDAQ:KALA ) have power over the company. Institutions will...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...
Kala Pharmaceuticals, Inc (KALA) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
